Reversible severe hereditary hemochromatotic cardiomyopathy.
Two cases of severe hereditary hemochromatotic cardiomyopathy are reported. Both patients responded remarkably well to treatment and are leading a normal life requiring no cardiac medications, following small volume phlebotomies for two years combined, in the first three and six months of treatment, with subcutaneous deferoxamine mesylate.
Madani
T A
TA
Department of Medicine, University of Ottawa, Ontario. tmadani@kaau.edu.sa
Bormanis
J
J
D000328:Adult; D009202:Cardiomyopathies / Q000188:drug therapy / Q000235:genetics* / Q000628:therapy*; D003676:Deferoxamine / Q000627:therapeutic use; D006432:Hemochromatosis / Q000188:drug therapy / Q000235:genetics* / Q000628:therapy*; D006801:Humans; D008297:Male; D018962:Phlebotomy; D012720:Severity of Illness Index; D017262:Siderophores / Q000627:therapeutic use
D017262:Siderophores; D003676:Deferoxamine